A Company Leveraging AI and Machine Learning for Innovative Protein Design

Samsung Life Science Fund Invests in U.S. Biotech ‘Generate Biomedicines’

Factory Construction to Begin in H1 Next Year; Targeting 3 Trillion KRW in Revenue by 2031

Celltrion Launches CDMO Subsidiary ‘BioSolutions’

Promising Preclinical Data; Patient Dosing Set to Begin Early Next Year

FDA Approves Liga-Chem Bio’s IND for Novel ADC Cancer Therapy

Plans Underway for Regulatory Approval in Northeast Asia

Cenobamate Proven Effective for Patients in Korea, China, and Japan

Aiming to Provide an Effective Platform for Potential Partners Interested in SC Formulation Development

Alteogen Receives USD 20 Million Upfront Payment from Daiichi Sankyo

First Female Professional CEO in Samsung Group’s history

Samsung Bioepis Appoints Kim Kyung-ah as New CEO After 13 Years

Presented at the Asia-Pacific Digestive Disease Week

Daewoong "Ursa Shows Liver Function Improvement in Phase 4 Trial"

Celltrion Secures First Approval for Prolia Biosimilar in Korea

Signs 930.4 Billion KRW Contract with European Pharmaceutical Company

Samsung Biologics Breaks 5 Trillion KRW in Annual Orders for the First Time

Accelerated Global Expansion Expected

FDA Approved VUNO’s AI Chest X-ray Diagnostic Device

First Major Pharma Collaboration... Expansion Beyond Lung Cancer Expected

Lunit Partners with AstraZeneca to Develop ‘AI Pathology Solution’

"Switching to Direct Sales Model"

Celltrion Acquires Swiss Pharmaceutical Distributor, iQone Healthcare Switzerland

Park Soon-Jae, CEO of Alteogen: “Creating a ‘Golden Egg’ Platform”

Global Pharma Companies Lining Up at Alteogen's Door – Why?

The event comprised lecture and live demonstration for facial filler injection

Hugel Successfully Concludes HA Filler workshop for French medical experts

echnology to Develop Subcutaneous Injection for ADC Cancer Drug 'Enhertu'

Alteogen Signs USD 280 Million Licensing Agreement with Daiichi Sankyo

Operating profit up 54.5% to 53.4 billion KRW

Hugel Sees Record Q3 Revenue and Profit with Botulax Growth

Acquires 31.5% Stake, Secures Production Base for Hyaluronidase Raw Materials

Huons Acquires PanGen... “Expanding CDMO Services for Biopharmaceuticals”

"Lower Incidence of Brain Hemorrhage and Edema in East Asians"

Korean Dementia Association: “Leqembi's Side Effects Are Not Significant”

Exceeds Last Year's Performance in Just Three Quarters

Samsung Bioepis Projected to Reach 1.4 Trillion KRW in Sales

Success from Co-Promotion of K-CAB and Legacy Brands Acquisition

Boryung Nearing 1 Trillion KRW in Annual Sales for the First Time